Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Metabolism - Volume 74, September 2017, Pages 43-46

Niki Katsiki, Vasilios G. Athyros, Dimitri P. Mikhailidis, Christos Mantzoros,